Skip to main content
Skip to section navigation
Skip to footer
Home
About
Overview
Management Team
Board of Directors
Advisory Board
Pipeline
Overview
XRx-026 for Gout
XRx-008 for Autosomal Dominant Polycystic Kidney Disease
XRx-101 for Coronavirus/COVID-19
225 for Type 2 Diabetic Nephropathy
Publications
Technology
News & Media
Press Releases
Events
In the News
Investors
Overview
News & Events
Presentations
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR+
Governance
Contact
Press Releases
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Presentations
Company Info
Overview
Management Team
Contacts
FAQ
Financial Info
Financial Results
Stock Data
Analyst Coverage
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
SEDAR+
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Board Diversity Matrix
Year
All Years
2025
2024
2023
2022
2021
2020
2019
2018
Sep 20, 2021 4:46pm EDT
XORTX Therapeutics Announces Share Consolidation
Sep 02, 2021 2:26pm EDT
XORTX Therapeutics Reports Special Meeting Results
Sep 01, 2021 7:00am EDT
XORTX Announces Grant of European Patent
Aug 31, 2021 9:11am EDT
XORTX Announces New Clinical Advisory Board Member
Aug 13, 2021 5:00pm EDT
XORTX Therapeutics Calls Special Meeting of Shareholders
Jul 14, 2021 7:00am EDT
XORTX Therapeutics Strengthens Executive Team
Jun 30, 2021 7:00am EDT
Dr. Stephen Haworth Joins XORTX Management Team
Jun 17, 2021 7:00am EDT
XORTX Welcomes Jaqueline Le Saux to Board of Directors
May 13, 2021 7:00am EDT
XORTX Welcomes New Member to Board of Directors
Apr 06, 2021 7:00am EDT
XORTX Announces Notice to Grant European Patent
arrow_back
1…
7
8
9
10
11
12
13
14
15
16
…18
arrow_forward
rss_feed
News RSS
Email Alerts
Contacts
RSS News Feed